Drugs / C1K
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05701644 | Jan → Jun 2023 | — | Ensol Bioscience | Completed | No outcome recorded |
| Phase 1 | NCT05980065 | Dec 2022 → Jun 2023 | — | Seoul National University Hospital | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C1K | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05701644 ↗ |
| Route | Subcutaneous | “Subcutaneously administrate C1K 150mg at Day 1, Day 8, Day 15” NCT05701644 ↗ |